MétaCan
Menu
Back to cohort
Record W4403834171 · doi:10.1681/asn.2024k1xwnxgq

Successful Use of Eculizumab for Prevention of Atypical Hemolytic Uremic Syndrome Recurrence in a Pregnant Kidney Transplant Recipient with CFH Gene Mutation: A Case Report and Literature Review

2024· article· en· W4403834171 on OpenAlexaff
Somaya Zahran, Thomas Nodzynski, Catherine Matte, Shaifali Sandal, Tiina Podymow, Marcelo Cantarovich

Bibliographic record

VenueJournal of the American Society of Nephrology · 2024
Typearticle
Languageen
FieldImmunology and Microbiology
TopicComplement system in diseases
Canadian institutionsLakeshore General HospitalMcGill University
Fundersnot available
KeywordsAtypical hemolytic uremic syndromeEculizumabMedicineThrombotic microangiopathyRenal transplantNephrologyKidneyInternal medicineImmunologyGastroenterologyIntensive care medicineComplement systemAntibodyDisease

Abstract

fetched live from OpenAlex

Introduction: Eculizumab is a humanized monoclonal antibody targeting C5, used in the treatment of atypical hemolytic uremic syndrome (aHUS). It is accepted as maintenance therapy for the prevention of recurrent aHUS post kidney transplant (KTx), however, clinical experience with its use during pregnancy is limited. Case Description: 36-year-old woman with history of end stage renal disease secondary to aHUS with confirmed complement factor H gene mutation was treated with hemodialysis, plasmapheresis, rituximab and vincristine. She received a standard-criteria deceased donor KTx in 2013. Eculizumab was administered in the perioperative period at a dose of 1200 mg IV, followed by 1200 mg Q1W for 2 weeks, and then Q2W thereafter as maintenance therapy. In 2016, she had a planned pregnancy during which eculizumab was continued. Biomarkers of hemolysis and kidney function were closely monitored. Despite the development of pre-eclampsia resulting in preterm delivery at 33W, the patient delivered a healthy infant and had well-preserved allograft function with no aHUS recurrence. 8 years later, no complications are observed and her child is developing normally. Pubmed search was conducted for reports of prophylactic use of eculizumab in aHUS pregnant KTx recipients between 1993 and 2024. 35 articles were found, of which, three fulfilled our criteria (table 1). Discussion: Although eculizumab is considered safe during pregnancy, its use in pregnant KTx recipients is rare given the lack of relevant pharmacological data and unknown long-term effects on the offspring. We report for the first time, 8-year follow up favorable maternal and fetal outcomes and provide a literature review of similar cases. We conclude that maintenance eculizumab is a plausible option for prevention of aHUS recurrence in pregnant women who received KTx. Close monitoring of hemolytic markers and kidney function is recommended to ensure early detection and management of complications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Case report · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.849
Threshold uncertainty score0.326

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.289
Teacher spread0.269 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designCase report
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of NephrologySame topicComplement system in diseasesFrench-language works237,207